Growth Metrics

Myomo (MYO) Amortization of Deferred Charges (2020 - 2021)

Myomo posted quarterly Amortization of Deferred Charges of -$99947.0 for Q2 2021, down 349.87% year-on-year from $40000.0 in Q2 2020, and down 159.99% on a QoQ basis from $166600.0 in Q1 2021.

Myomo (MYO) has 2 years of Amortization of Deferred Charges data on file, last reported at -$99947.0 in Q2 2021.

  • For the quarter ending Q2 2021, Amortization of Deferred Charges fell 349.87% year-over-year to -$99947.0; the trailing twelve-month figure through Jun 2021 stood at $78753.0 (down 26.49% YoY), and the FY2020 full-year result was $161869.0, up 177.67% from the prior year.
  • Amortization of Deferred Charges for Q2 2021 stood at -$99947.0, down from $166600.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $166600.0 in Q1 2021 and bottomed at -$99947.0 in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Myomo 44.63 Mn 26.23 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2021 -99,947.00
Jun 30, 2021 -99,947.00
Mar 31, 2021 166,600.00
Mar 31, 2021 166,600.00
Sep 30, 2020 12,100.00
Sep 30, 2020 12,100.00
Jun 30, 2020 40,000.00
Jun 30, 2020 40,000.00
Mar 31, 2020 67,132.00
Mar 31, 2020 67,132.00